

Sensitizing tumor cells to radiotherapy

1 March 2012

Head and neck squamous cell carcinoma (HNSCC) is the fifth most common cancer worldwide. Tumor resistance to radio- and/or chemotherapy remains a significant clinical problem.

A team of researchers led by Nils Cordes, at Dresden University of Technology, Germany, has now identified a way to enhance the sensitivity of human HNSCC cell lines to radiation such that their growth is delayed in xenografted mice.

In the study, Cordes and colleagues determined that a beta-1 integrin/FAK/cortactin signaling pathway is crucial for HNSCC resistance to radiotherapy. Inhibiting beta-1 integrin sensitized HNSCC cells to radiotherapy and delayed [tumor growth](#) in xenografted mice. Thus, Cordes and colleagues suggest that targeting beta-1 integrin could be used in combination with radiotherapy and radiochemotherapy to increase the survival of patients with HNSCC.

More information: Beta-1 integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy, *Journal of Clinical Investigation*.

Provided by Journal of Clinical Investigation

APA citation: Sensitizing tumor cells to radiotherapy (2012, March 1) retrieved 18 October 2022 from <https://medicalxpress.com/news/2012-03-sensitizing-tumor-cells-radiotherapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.